The present invention relates to novel endolysin polypeptides or fragments thereof which possess antimicrobial activity, preferably antibacterial activity against Clostridium perfringens. The invention also relates to a nucleic acid molecule encoding the endolysin polypeptide or fragment, a recombinant polynucleotide expression vector comprising such a nucleic acid molecule, as well as a host cell comprising such a nucleic acid molecule or comprising such a recombinant polynucleotide expression vector. The invention also relates to compositions and foodstuffs comprising the endolysin polypeptides or fragments and uses thereof in the treatment of diseases or disorders in animals.

A method of using ZnO particles for the treatment of colon cancer and a method of using the particles for reducing the concentration of an organic contaminant in an aqueous solution is described. The ZnO particles are substantially spherical and may have nanopetals that provide a nanoflower morphology. The synthesis and characterization of the ZnO particles is also discussed.

A method of using ZnO particles for the treatment of colon cancer and a method of using the particles for reducing the concentration of an organic contaminant in an aqueous solution is described. The ZnO particles are substantially spherical and may have nanopetals that provide a nanoflower morphology. The synthesis and characterization of the ZnO particles is also discussed.

A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells, (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and/or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.

The present invention discloses an application of Bacteroides cellulosilyticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases, such as atherosclerosis related diseases, cardiovascular diseases and obesity.

The present invention discloses an application of Bacteroides cellulosilyticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases, such as atherosclerosis related diseases, cardiovascular diseases and obesity.

The present invention relates to a novel Lactobacillus sakei WIKIM30 (Accession No. KCCM11878P) isolated from kimchi and a composition comprising the same as an active ingredient. Lactobacillus sakei WIKIM30 according to the present invention shows excellent anti-cancer activity in animal models in which a cancer cell is transplanted and cancer cell lines, and therefore it can be usefully used as a composition in use of treatment, prevention or improvement of cancer of humans or animals.

This disclosure provides materials and methods for reducing production of virulence factors in C. perfringens and or other pathogenic clostridia with related Agr-like QS systems using compounds that interfere with the Agr-like quorum sensing (QS) system. For example, Agr-like QS system inhibitors based on peptidomimetic compounds of the Agr-like QS system signaling peptide (SP) or the SP receptor of C. perfringens, and methods of using the Agr-like QS system inhibitors to prevent, treat, or ameliorate a disease associated with C. perfringens infection are provided.

This disclosure provides materials and methods for reducing production of virulence factors in C. perfringens and or other pathogenic clostridia with related Agr-like QS systems using compounds that interfere with the Agr-like quorum sensing (QS) system. For example, Agr-like QS system inhibitors based on peptidomimetic compounds of the Agr-like QS system signaling peptide (SP) or the SP receptor of C. perfringens, and methods of using the Agr-like QS system inhibitors to prevent, treat, or ameliorate a disease associated with C. perfringens infection are provided.

Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Use of said composition in methods of reducing triglycerides or reducing C-reactive protein levels are also provided.